When AV access, peripheral bypass, and abdominal aortic vascular infections occur, surgeons need reliable solutions. CryoVein and CryoArtery are ideal choices to treat vascular infections that may contain gram positive, gram negative, and fungal pathogens.1-6
|Up to 19% of patients have infected synthetic hemodialysis access grafts7
||Up to 5% of patients have infected peripheral synthetic bypass grafts8
||Up to 3.5% of patients experience abdominal aortic infections9 due to synthetic graft infections, mycotic aneurysms, or aorto-enteric fistulas
Allograft Features & Benefits:
- Resistance to Infection: Gram positive, gram negative, and fungal pathogens1-6
- Structural Durability: No reports of aneurysm or dilation in four U.S. studies2-5
- Cost effectiveness: The allograft group cost 40% less than the conventional group (p=0.005) when treating abdominal aortic infections1
- Duration of Hospitalization: The allograft group had 47% less days (14 days vs. 30 days) than the conventional group (p=0.002)1
- Time in ICU: The allograft group had 90% less days (median 1 day vs. 11 days) than the conventional group (p=0.001)1
1. Vogt P et al. J Thorac Cardiovasc Surg 1998;116:965-72.
2. Brown K et al. J Vasc Surg 2009;49:660-6.
3. Noel A et al. J Vasc Surg 2002;35:847-852.
4. Zhou W et al. Tex Heart Inst J 2006;33:14-8.
5. McCready R et al. Ann Vasc Surg 2006 Sep;20(5):590-5.
6. CryoLife data on file.
7. Akoh J. Prosthetic arteriovenous grafts for hemodialysis. J Vasc Access 2009;10:137-47.
8. Back M. Rutherford’s Vascular Surgery (7th ed.), Philadelphia, PA: Saunders Elsevier. 2010;1.
9. Bisdas, et al. J Vasc Surg 2010